The COMPEL study provides the first formal data supporting the common practice of continuing osimertinib when adding chemotherapy after disease progression. This is a significant finding as previous studies with older-generation TKIs showed this strategy was not helpful, highlighting osimertinib's unique CNS-protective benefits.

The COMPEL study showed a near doubling of progression-free survival by continuing osimertinib with chemotherapy after first-line progression. This contradicts findings with first-generation TKIs (like gefitinib) and establishes "TKI continuation" as a new standard of care.

The NeoADURA trial demonstrates that adding osimertinib in the neoadjuvant setting for EGFR-mutated NSCLC results in a 'humongous benefit' in major pathological response and nodal downstaging compared to chemotherapy alone, significantly improving surgical outcomes.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

When EGFR+ NSCLC transforms to small cell, clinicians often continue the TKI osimertinib alongside chemotherapy. This practice is largely based on expert consensus and the rationale of suppressing any remaining EGFR-driven clones, rather than on definitive clinical trial data showing a clear benefit.

Data from the ADAURA trial suggests that EGFR-mutated lung cancer patients with detectable ctDNA before starting adjuvant osimertinib are at very high risk of recurrence. This finding supports considering indefinite, lifelong osimertinib for this subgroup, deviating from the standard three-year duration.

Despite initial benefits, fewer than 10% of EGFR-mutated NSCLC patients on osimertinib monotherapy survive five years. A significant portion (25-40%) never even receive a second-line treatment, highlighting the limitations of this once-standard approach.

The COMPEL trial provides strong evidence for a "treat through progression" strategy. For patients progressing on osimertinib monotherapy, continuing the TKI while adding chemotherapy significantly reduces the probability of CNS progression, highlighting its role as a CNS protectant even when systemic efficacy is waning.

While research pursues mechanism-based strategies (e.g., 4th-gen TKIs) for acquired resistance, recent practical breakthroughs are mechanism-agnostic, like ADCs or chemotherapy combinations. This highlights a pragmatic, broad-spectrum approach to treating progression after frontline osimertinib.